Abstract
Ipatasertib is a potent and selective small-molecule inhibitor of all three isoforms of the serine/threonine kinase AKT. Its beneficial use as a single-agent or in combination with chemotherapeutic, hormonal, or targeted agents for patients (pts) with metastatic breast cancer is supported by in vivo results. Pathfinder is evaluating the safety, tolerability, and preliminary efficacy of ipatasertib in combination with non-taxane chemotherapy agents in taxane-pretreated unresectable advanced TNBC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
